According to Zhitong Finance App News, Xinbang Pharmaceutical (002390.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 2,467 billion yuan, down 13.29% from the same period of the previous year; net profit attributable to shareholders of listed companies was 99.5863 million yuan, down 7.1% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 76.361 million yuan, down 28.13% from the same period last year; basic earnings per share were 0.0525 yuan. The company plans to distribute a cash dividend of 0.3 yuan (tax included) for every 10 shares to all shareholders.

According to Zhitong Finance App News, Xinbang Pharmaceutical (002390.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 2,467 billion yuan, down 13.29% from the same period of the previous year; net profit attributable to shareholders of listed companies was 99.5863 million yuan, down 7.1% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 76.361 million yuan, down 28.13% from the same period last year; basic earnings per share were 0.0525 yuan. The company plans to distribute a cash dividend of 0.3 yuan (tax included) for every 10 shares to all shareholders.